Erythropoietin levels in children with obstructive sleep apnea

xlomafota13 shared this article with you from Inoreader Erythropoietin levels in children with obstructive sleep apnea Via International Journal of Pediatric Otorhinolaryngology Publication date: Available online 1 October 2021 Source: International Journal of Pediatric Otorhinolaryngology Author(s): Nick D. Kalogritsas, Vasileios A. Lachanas, Panagiotis Liakos, Emmanuel I. Alexopoulos, Despoina Beka, Efthymia Petinaki, Jiannis Hajiioannou, George Simos, Charalampos E. Skoulakis View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Treatment of burn contractures with allogeneic human dermal fibroblasts improves Vancouver scar scale: A phase I/II trial

xlomafota13 shared this article with you from Inoreader Treatment of burn contractures with allogeneic human dermal fibroblasts improves Vancouver scar scale: A phase I/II trial Via Journal of plastic, reconstructive & aesthetic surgery : JPRAS J Plast Reconstr Aesthet Surg. 2021 Sep 17:S1748-6815(21)00405-8. doi: 10.1016/j.bjps.2021.08.018. Online ahead of print. NO ABSTRACT PMID:34593339 | DOI:10.1016/j.bjps.2021.08.018 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Does Frailty or Age Increase the Risk of Postoperative Complications Following Cochlear Implantation?

xlomafota13 shared this article with you from Inoreader Does Frailty or Age Increase the Risk of Postoperative Complications Following Cochlear Implantation? Via leak of cerebrospinal fluid OTO Open. 2021 Sep 24;5(3):2473974X211044084. doi: 10.1177/2473974X211044084. eCollection 2021 Jul-Sep. ABSTRACT OBJECTIVE: To evaluate whether frailty or age increases the risk of postoperative complications following cochlear implant (CI) surgery. STUDY DESIGN: Retrospective cohort study. SETTING: Tertiary academic center. METHODS: An evaluation of all adult patients undergoing cochlear implantation between 2006 and 2020 was performed. The 5-item Modified Frailty Index (mFI-5, comprising preoperative history of pulmonary disease, heart failure, hypertension, diabetes, and partially/totally dependent functional status) was calculated for all patients included in analysis in addition to demographic characteristics. The primary outcome was postoperative complications following CI within a 3-month period. Major complications included myocardial infarction, bleeding, and cerebrospinal fluid leak, among others. Predictors of pos toperative complications were examined using multivariable logistic regression reporting odds ratios (ORs) and 95% CIs. RESULTS: There were 520 patients included for review with a median age of 68 (range, 18-94) years and a slight male predominance (n = 283, 54.4%). There were 340 patients (65.4%) who were robust (nonfrail) with an mFI of 0, while 180 (34.6%) had an mFI of ≥1. There were 20 patients who experienced a postoperative complication (3.85%). There was no statistically significant association between postoperative complications as a result of preoperative frailty (OR, 1.56; 95% CI, 0.98-2.48, P = .06) or age as a continuous variable (OR, 0.99; 95% CI, 0.97-1.02, P = .51). CONCLUSIONS: CI is safe for elderly and frail patients and carries no additional risk of complications when compared to younger, healthier patients. While medical comorbidities should always be considered perioperatively, this study supports the notion that implantation is low risk in older, frail patients. PMID:34595366 | PMC:PMC8477701 | DOI:10.1177/2473974X211044084 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib

xlomafota13 shared this article with you from Inoreader Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib Via radioactive iodine Cureus. 2021 Aug 27;13(8):e17488. doi: 10.7759/cureus.17488. eCollection 2021 Aug. ABSTRACT Radioactive iodine-refractory metastatic differentiated thyroid cancer (RAIR) is associated with a poor prognosis. Multikinase inhibitors have demonstrated improvement in progression-free but not overall survival in such patients, but usage is limited by significant adverse effects and the development of resistance. Clinical research has demonstrated improvement in progression-free survival with the combined use of the BRAF/MEK inhibitor in patients with metastatic melanoma and anaplastic thyroid cancer with the BRAFV600E mutation and has shown promise in redifferentiation of BRAF-positive RAIR differentiated thyroid cancer. A 58-year-old woman went to her primary care physician for a growing mass on the left side of her neck. CT imaging noted a 6 x 8 x 6 cm mixed cystic and solid mass and lymphadenopathy. Core biopsy subsequently showed metastatic papillary thyroid cancer (Stage III, PT4a/PN1b), and she underwent a total thyroidectomy with left neck dissection. She then received 204mCi 131I post-total thyroidectomy. Unfortunately, her thyroglobulin continued to increase post-radioactive iodine (RAI) treatment, indicating persistent and/or recurrent thyroid cancer. An RAI-131 whole-body scan on the thyrogen protocol showed no significant RAI uptake. A fluorodeoxyglucose (FDG)-positron emission tomography (PET) CT scan was then performed, which sho wed recurrent metastatic disease with hypermetabolism noted in the left thyroid bed and FDG-avid bilateral cervical lymph nodes and pulmonary nodules. Given these findings, her cancer was classified as radioactive iodine refractory (RAIR). Molecular testing indicated the BRAFV600E mutation. After a discussion with the patient, it was decided to initiate therapy with a BRAF inhibitor (dabrafenib 150 mg twice a day) and MEK inhibitor (trametinib 2 mg once a day) in an attempt to redifferentiate RAIR. Repeat RAI-131 thyrogen whole body scan one month after initiation of therapy demonstrated left level 2 cervical lymphadenopathy radioiodine uptake. The patient subsequently received 216 mCi 131I treatment given evidence of redifferentiation. Her post-treatment scan indicated additional uptake in a left lower lobe pulmonary nodule as well as a left paratracheal mass indicating successful RAI-131 uptake by metastases. Her thyroglobulin level, six months post-RAI, decr eased to 4.0 indicating an encouraging response. Further surveillance, including imaging studies, is planned. This case illustrates the re-differential potential for dabrafenib and trametinib treatment in patients with BRAFV600E-mutated RAIR differentiated thyroid cancer. This therapy has been shown to be successful in small series of patients and could potentially be offered to RAIR patients with the BRAFV600E mutation as an alternative to multikinase treatment given its favorable side-effect profile. PMID:34595070 | PMC:PMC8465644 | DOI:10.7759/cureus.17488 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Conjunctivoductivo‐Dacryocystorhinostomy: A Novel Surgery for Intractable Canalicular Obstruction

xlomafota13 shared this article with you from Inoreader Conjunctivoductivo‐Dacryocystorhinostomy: A Novel Surgery for Intractable Canalicular Obstruction Via The Laryngoscope View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Insulin-like growth factor 1 promotes neurological functional recovery after spinal cord injury through inhibition of autophagy via the PI3K/Akt/mTOR signaling pathway

xlomafota13 shared this article with you from Inoreader Insulin-like growth factor 1 promotes neurological functional recovery after spinal cord injury through inhibition of autophagy via the PI3K/Akt/mTOR signaling pathway Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1265. doi: 10.3892/etm.2021.10700. Epub 2021 Sep 6. ABSTRACT Spinal cord injury (SCI) is a serious trauma; however, the mechanisms underlying the role of insulin-like growth factor 1 (IGF-1) in autophagy following SCI remain to be elucidated. The present study aimed to investigate the therapeutic effect of IGF-1 on SCI and to determine whether IGF-1 regulates autophagy via the PI3K/Akt/mTOR signaling pathway. SH-SY5Y neuroblastoma cells were assigned to the H2O2, IGF-1 and control groups to investigate subsequent neuron injury in vitro. An MTT assay was performed to evaluate cell survival. In addition, Sprague-Dawley rats were randomly assigned to SCI, SCI + IGF-1 and sham groups, and Basso-Beatlie-Bresnahan scores were assessed to determine rat neurological function. Western blotting was used to analyze the autophagy level and the activation of the PI3K/Akt/mTOR signaling pathw ay. Cell survival was increased significantly in the IGF-1 group compared with the control group in vitro (P<0.05). Furthermore, neurological function was improved in the SCI + IGF-1 group compared with the control group in vivo (P<0.05). The western blotting results further demonstrated that LC3II/LC3I expression was increased in the IGF-1 group compared with the sham group in vivo and compared with the control group in vitro (both P<0.05). In the SCI + IGF-1 group, the expression levels of PI3K, phosphorylated (p)-Akt and p-mTOR were higher compared with those in the sham and SCI groups in vivo (P<0.05). Moreover, in the IGF-1 group, the expression levels of p-Akt and p-mTOR were higher compared with the control and the H2O2 groups in vitro (P<0.05). Collectively, the results of the present study suggested that IGF-1 promoted functional recovery in rats following SCI through neuroprotective effects. Furthermor e, the underlying mechanism may involve activation of the PI3K/Akt/mTOR signaling pathway, followed by inhibition of autophagy. However, further investigation into the association between IGF-1-regulated autophagy and the activation of different subtypes of PI3K is required. PMID:34594402 | PMC:PMC8456500 | DOI:10.3892/etm.2021.10700 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review)

xlomafota13 shared this article with you from Inoreader Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1267. doi: 10.3892/etm.2021.10702. Epub 2021 Sep 7. ABSTRACT Peritoneal carcinomatosis, as well as the presence of liver metastases from colorectal cancer, has been long considered as the sign of a systemic disease, transforming the patient into a candidate for palliation and best supportive care. However, in recent decades, progress in the field of medical and surgical oncology has allowed scientists worldwide to produce curative therapeutic strategies for these cases such as hyperthermic intraperitoneal chemotherapy (HIPEC) or extended liver resection. In addition, the association of these two therapies has also been performed with encouraging results. The aim of the current study was to review articles published thus far in regard to the association of these two therapeutic strategies, in order to identify which cases can benefit the most, which is the most efficient agent or combination of agents, and w hether these types of therapy should be performed as monotherapy or as a two-stage procedure. PMID:34594404 | PMC:PMC8456510 | DOI:10.3892/etm.2021.10702 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.